London Healthcare Week: The CEO of Arbutus summarizes IM-PROVE I phase 2a data for imdusiran in chronic hepatitis B presented earlier this week at The Liver Meeting

Michael McElhaugh describes how 25% of patients overall, and 50% of patients who had low baseline levels of hepatitis B surface antigen, saw a functional cure. Given this learning, he also discusses the potential development plan going forward.